First-Line Crizotinib in ALK-Positive Lung Cancer (vol 372, pg 781, 2015)

被引：0
|
作者：
Tural, Deniz
Saadettin, Kilickap
Akan, Ali
Koksoy, Elif B.
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 372卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：887 / 887
页数：1
相关论文
共 50 条
  • [21] Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
    Ji, Cheng
    Zhang, Li
    Cheng, Yan
    Patel, Raj
    Wu, Hao
    Zhang, Yi
    Wang, Mian
    Ji, Shundong
    Belani, Chandra P.
    Yang, Jin-Ming
    Ren, Xingcong
    CANCER BIOLOGY & THERAPY, 2014, 15 (05) : 570 - 577
  • [22] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
    Chuang, Jody C.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
  • [23] Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma
    Zheng, Zhe-Rong
    Wu, Jia-Jun
    Chiang, Chun-Ju
    Chen, Tzu-, I
    Chen, Kun-Chieh
    Chu, Cheng-Hsiang
    Lin, Sheng-Yi
    Yu, Sung-Liang
    Lee, Wen-Chung
    Liu, Tsang-Wu
    Chang, Gee-Chen
    TARGETED ONCOLOGY, 2024, 19 (06) : 941 - 955
  • [24] Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey S.
    Krahn, Murray
    Tsao, Ming-Sound
    Cutz, Jean-Claude
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1012 - +
  • [25] An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
    Zhou, Yourong
    Yin, Yiming
    Xu, Jiangxin
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (12) : 1361 - 1373
  • [26] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Cruz, Barbara D.
    Barbosa, Mariana M.
    Torres, Lucas L.
    Azevedo, Pamela S.
    Silva, Vania E. A.
    Godman, Brian
    Alvares-Teodoro, Juliana
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 505 - 524
  • [27] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Barbara D. Cruz
    Mariana M. Barbosa
    Lucas L. Torres
    Pamela S. Azevedo
    Vânia E. A. Silva
    Brian Godman
    Juliana Alvares-Teodoro
    Oncology and Therapy, 2021, 9 : 505 - 524
  • [28] J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
    Gainor, Justin F.
    Shaw, Alice T.
    LANCET, 2017, 390 (10089): : 3 - 4
  • [29] Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib
    Awad, Mark M.
    Lax, Timothy P.
    Slawski, Benjamin R.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1726 - 1728
  • [30] Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma
    Zito Marino, Federica
    Morabito, Alessandro
    Gridelli, Cesare
    Rocco, Gaetano
    Liguori, Giuseppina
    De Rosa, Nicla
    Botti, Gerardo
    Franco, Renato
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (09) : E86 - E88
12345